Skinvisible Unveils Promising Data on Transdermal Obesity Formulations

Rhea-AI Summary

Skinvisible has announced promising data on its transdermal delivery system for obesity drugs using Invisicare technology. The company reported significant penetration rates for GLP-1 receptor agonists and CB-1 receptor antagonists, achieving up to 69% and 62% penetration respectively over six hours. The formulations offer sustained drug release, potentially avoiding the side effects of oral pills and injections, and improving patient compliance. The global obesity market is projected to reach $24 billion in 2023 and $131 billion by 2028. Skinvisible is seeking strategic partnerships to commercialize these therapies.

Positive

• Skinvisible's Invisicare technology demonstrated up to 69% penetration for GLP-1 receptor agonists and 62% for CB-1 receptor antagonists over six hours.
• The formulations provide sustained drug release, approximately 10% per hour.
• Potential to bypass side effects of oral pills and injections, improving patient compliance.
• The global obesity market is expected to reach $131 billion by 2028, presenting a significant market opportunity.

Negative

• None.

Results Demonstrate Significant Transdermal Penetration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology

LAS VEGAS, NV / ACCESSWIRE / July 9, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical pharmaceutical research and development company, today announced exciting data demonstrating its transdermal delivery of obesity drugs (and other glucose- controlling drugs) including a GLP-1 agonist and CB-1 receptor antagonist delivered by its proprietary Invisicare® technology; a polymer delivery vehicle that does not require a patch or needles. The Company previously announced it has filed two provisional patent applications covering formulations that leverage Invisicare for the transdermal administration of obesity drugs and other glucose-controlling agents.

The Company has been developing topical formulations to enable transdermal absorption of these drugs, allowing for sustained release into the bloodstream. The results are compelling:

• Franz Cell diffusion studies demonstrated up to 69% penetration over six hours for the GLP-1 drug tested;

• For the CB-1 antagonists formulated with Invisicare, a 62% penetration rate was achieved over the same time period;

• In addition to these high penetration rates, these studies demonstrate that Invisicare formulations have the ability to provide sustained drug delivery over time. Data showed an average drug release of approximately 10% per hour.

Building on this breakthrough, Skinvisible is confident that its proprietary technology can be applied to a broader range of GLP-1 agonists and CB-1 receptor antagonists with a molecular mass that permits transdermal penetration. This development opens up exciting possibilities for expanding the company's portfolio of obesity-targeting formulations.

"Our Invisicare technology has the potential to revolutionize how obesity drugs are administered," said Terry Howlett, Skinvisible's CEO. "We can deliver significant amounts of drug systemically, potentially avoiding the side effects of oral pills and injections and increase patient compliance." He explained, "Since pills must pass through the digestive system and liver first, much of the drug is metabolized before reaching its target and may lead to uncomfortable side-effects. Injections can be painful and lead to poor patient compliance. Our topical cream formulations offer a transdermal approach that circumvents first-pass metabolism and related challenges. Furthermore, these transdermal obesity treatments could serve effectively as a maintenance therapy."

Skinvisible has pursued the obesity market due to the overwhelming increase in the need for obesity drugs and treatment options. According to a recent IQVIA report, the prevalence of obesity in the world is expected to be 25% of the population by 2035. In conjunction with the increase in obesity, the global obesity market is expected to reach $24 billion in 2023, and a staggering $131 billion by 2028.

Skinvisible is actively seeking a strategic partnership with a pharmaceutical and/or biotech company to bring the first transdermal obesity therapies to market and to explore applications of its transdermal delivery platform across other disease areas.

For more information on Skinvisible Pharmaceuticals, partnerships and investment opportunities, please visit www.skinvisible.com or contact info@skinvisible.com.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby including with respect to the possible development of any such products, the acceptance of any such products in the market place, the size of any such markets, the ability of any product candidates to be approved by the U.S. Food and Drug Administration among others. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending March 31, 2024).

###

Contacts:

• Strategic Partnerships: Doreen McMorran - doreen@invisicare.com

• Corporate Inquiries: info@skinvisible.com

• Office Number: 702-433-7154 (PST)

SOURCE: Skinvisible, Inc.

View the original press release on accesswire.com

FAQ

What did Skinvisible announce about its transdermal obesity formulations?

Skinvisible announced promising data demonstrating significant transdermal penetration rates for GLP-1 receptor agonists and CB-1 receptor antagonists using its Invisicare technology.

How effective is Skinvisible's Invisicare technology in delivering obesity drugs?

Franz Cell diffusion studies showed that Invisicare technology achieved up to 69% penetration for GLP-1 receptor agonists and 62% for CB-1 receptor antagonists over six hours.

What is the projected market size for obesity treatments?

The global obesity market is expected to reach $24 billion in 2023 and grow to $131 billion by 2028.

What strategic steps is Skinvisible taking with its new technology?

Skinvisible is seeking strategic partnerships with pharmaceutical and biotech companies to bring transdermal obesity therapies to market and explore other applications of its delivery platform.

What are the benefits of Skinvisible's transdermal drug delivery system?

The system potentially avoids side effects of oral pills and injections, improves patient compliance, and offers sustained drug release.